Axiom Investors LLC DE Acquires 63,480 Shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Axiom Investors LLC DE raised its holdings in Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 274.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 86,600 shares of the company’s stock after buying an additional 63,480 shares during the period. Axiom Investors LLC DE’s holdings in Dr. Reddy’s Laboratories were worth $1,367,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in the business. Robeco Institutional Asset Management B.V. grew its holdings in Dr. Reddy’s Laboratories by 453.8% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company’s stock worth $180,620,000 after buying an additional 9,373,412 shares in the last quarter. Van ECK Associates Corp grew its stake in shares of Dr. Reddy’s Laboratories by 609.4% in the 4th quarter. Van ECK Associates Corp now owns 5,838 shares of the company’s stock worth $92,000 after acquiring an additional 5,015 shares in the last quarter. Allspring Global Investments Holdings LLC raised its holdings in shares of Dr. Reddy’s Laboratories by 400.6% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 534,304 shares of the company’s stock valued at $8,373,000 after purchasing an additional 427,573 shares during the last quarter. World Investment Advisors LLC purchased a new position in Dr. Reddy’s Laboratories during the third quarter worth about $3,459,000. Finally, Crossmark Global Holdings Inc. grew its position in Dr. Reddy’s Laboratories by 328.3% in the 4th quarter. Crossmark Global Holdings Inc. now owns 12,760 shares of the company’s stock worth $201,000 after purchasing an additional 9,781 shares in the last quarter. 3.85% of the stock is currently owned by institutional investors and hedge funds.

Dr. Reddy’s Laboratories Stock Performance

NYSE RDY opened at $13.19 on Tuesday. The company has a market capitalization of $11.01 billion, a PE ratio of 21.00 and a beta of 0.48. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.38 and a current ratio of 1.92. Dr. Reddy’s Laboratories Limited has a 52-week low of $12.50 and a 52-week high of $16.89. The company has a 50-day simple moving average of $13.45 and a 200 day simple moving average of $14.58.

Dr. Reddy’s Laboratories (NYSE:RDY) last issued its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.19 by $0.01. Dr. Reddy’s Laboratories had a net margin of 17.25% and a return on equity of 17.87%. On average, research analysts predict that Dr. Reddy’s Laboratories Limited will post 0.8 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. StockNews.com cut shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, December 6th. Nomura lowered Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a report on Thursday, December 19th.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.